Skip to content

Evaluation of the efficacy of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) based on cardiopulmonary endurance testing (CPET) in patients with metabolically associated fatty liver disease (MAFLD)

Evaluation of the efficacy of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) based on cardiopulmonary endurance testing (CPET) in patients with metabolically associated fatty liver disease (MAFLD)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087703
Enrollment
Unknown
Registered
2024-08-01
Start date
2022-07-26
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

HIIT group:High-intensity intermittent exercise 3 times a week for 12 weeks
MICT group:Participate in moderate-intensity exercise three times a week for a period of 12 weeks.

Sponsors

Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Moderate MAFLD with IHCL=10% was measured by MRS At age 18-55. 2. Meet the 2006 IDF diagnostic criteria for metabolic syndrome; 3. Cardiorespiratory endurance test: VO2max=20ml/min/kg and PHR/HRmax=80%.

Exclusion criteria

Exclusion criteria: 1. Weekly alcohol intake female >140g or male > 210g; 2. Viral hepatitis or other acute and chronic liver diseases (ALT=3ULN or TBIL=2ULN); 3. Unstable angina pectoris or uncontrolled arrhythmia or cardiac insufficiency (NYHA2 or higher); 4. valvular heart disease or cardiomyopathy, renal insufficiency (eGFR-EPI16.7mmol/L or <4mmol/L; 4) Severe diabetic complications; 7. Lipid-lowering, hypertensive and hypoglycemic drugs should be used stably for more than 3 months; 8. Chronic obstructive pulmonary disease and other movement contraindications.

Design outcomes

Primary

MeasureTime frame
intrahepatocellular lipid (IHCL);

Secondary

MeasureTime frame
Body fat percentage;Muscle content;LDL-c;HDL-c;TG;FBG;HbA1c;ALT;AST;

Countries

Chian

Contacts

Public ContactPing Fan

Peking Union Medical College Hospital

pingfan6776@163.com+86 136 5109 1819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026